Sorrento Therapeutics (OTCMKTS:SRNEQ – Get Free Report) and Microbot Medical (NASDAQ:MBOT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.
This is a breakdown of recent ratings for Sorrento Therapeutics and Microbot Medical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Microbot Medical has a consensus target price of $8.00, indicating a potential upside of 296.04%. Given Microbot Medical’s higher probable upside, analysts clearly believe Microbot Medical is more favorable than Sorrento Therapeutics.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Sorrento Therapeutics has a beta of 2.23, indicating that its share price is 123% more volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 3.22, indicating that its share price is 222% more volatile than the S&P 500.
Earnings & Valuation
This table compares Sorrento Therapeutics and Microbot Medical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Sorrento Therapeutics||$62.84 million||1.84||-$572.84 million||N/A||N/A|
|Microbot Medical||N/A||N/A||-$13.17 million||($1.48)||-1.36|
Microbot Medical has lower revenue, but higher earnings than Sorrento Therapeutics.
Insider and Institutional Ownership
0.0% of Sorrento Therapeutics shares are owned by institutional investors. Comparatively, 15.2% of Microbot Medical shares are owned by institutional investors. 2.6% of Sorrento Therapeutics shares are owned by company insiders. Comparatively, 13.6% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Microbot Medical beats Sorrento Therapeutics on 7 of the 9 factors compared between the two stocks.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.
About Microbot Medical
Microbot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, a robotic system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination. In addition, it provides One & Done Technology, an endovascular robotic system for a range of applications in cardiovascular, peripheral vascular, and neurovascular spaces; and NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. Further, the company offers ViRob, an autonomous crawling micro-robot which can be controlled remotely to navigate and crawl in different natural spaces within the human body, including blood vessels, digestive tract, and respiratory system, as well as artificial spaces, such as shunts, catheters, ports, etc. Additionally, it provides ipCAT, a disposable self-propelled locomotive device that is designed to advance in tubular anatomies. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is headquartered in Hingham, Massachusetts.
Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.